Silexion Therapeutics Corp

Stage 4 · Declining · week 109

As of Oct 22, 2026, Silexion Therapeutics is in Stage 4, the downtrend phase, now in week 109 (since Aug 21, 2024). It closed at $0.17, 99.5% below its 52-week high and below its 200-day average, which is falling.

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. More about the company

$0.17

+0.86% today

$2.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SLXN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 52w

S4 113w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 52w → S3 1w → S4 113w current

Total tracked: 166 weeks across 3 stage runs.

SLXN among Biotechnology554th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…554	SLXNSilexion Therapeutics Corp	Stage 4 · wk 109	2	−47.6%

vs 52W High

-99.5%

$0.15 lo$34.70 hi

99.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 109

1w13w26w

Week 109, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-97.7%

200 DMA: $7.32 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.04x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-47.6%

-92.7%

-98.2%

YTD

-99.1%

-99.5%

Scan Membership

Breakout Watch

Latest: 2023-01-10

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 109 · Vol 0.04x

2026-10-21S4

Wk 109 · Vol 0.02x

2026-10-20S4

Wk 109 · Vol 0.09x

2026-10-19S4

Wk 109 · Vol 0.40x

2026-10-16S4

Wk 109 · Vol 0.07x

2026-10-15S4

Wk 108 · Vol 0.22x

2026-10-14S4

Wk 108 · Vol 0.06x

2026-10-13S4

Wk 108 · Vol 0.16x

2026-10-12S4

Wk 108 · Vol 0.10x

2026-10-09S4

Wk 108 · Vol 0.06x

2026-10-08S4

Wk 107 · Vol 0.12x

2026-10-07S4

Wk 107 · Vol 0.09x

Moving averages & range

50 DMA

$0.32

200 DMA

$7.32

52W High

$34.70

52W Low

$0.15

5D Low

$0.15

Resistance levels (recent highs)

20d High

$0.32

60d High

$1.95

120d High

$6.33

250d High

$34.70

Next resistance

+92.7%

to 20d High

Dividend Yield

0.00%

P/B 20.6

Silexion Therapeutics: quick answers

What stage is Silexion Therapeutics in?

As of Oct 22, 2026, Silexion Therapeutics (SLXN) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 21, 2024 and is in week 109. What the four stages mean

Is Silexion Therapeutics in an uptrend?

No. Silexion Therapeutics is in a Stage 4 downtrend. It trades 97.7% below its 200-day average, which is falling.

How far is Silexion Therapeutics from its 52-week high?

Silexion Therapeutics closed at $0.17 on Oct 22, 2026, 99.5% below its 52-week high of $34.70. Its 52-week low is $0.15.

How has Silexion Therapeutics performed over the past year?

As of Oct 22, 2026, Silexion Therapeutics is down 99.5% over the past year and down 99.1% so far in 2026.

Which sector and industry is Silexion Therapeutics in?

Silexion Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.